2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2248

Function, Pain, Fatigue, and Participation Are the Primary Contributors to the Patient Global Assessment in Rheumatoid Arthritis

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2589

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2171

Functional Measures and Patient Home Self-Assessments in the Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2716

Gastrointestinal Involvement in Adult IgA Vasculitis (Henoch–Schönlein purpura): Initial Manifestations and Outcomes

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2350

Gastrointestinal Microbiota in New-Onset Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2499

Gender Differences in Axial and Peripheral Spondyloarthritis: Results from the Esperanza Cohort

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2368

Global Circumferential Strain By Assessed a Feature Tracking Cardiac Magnetic Resonance (CMR) Imaging Was Associated with Myocardial Fibrosis in RA Patients

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2463

Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

9:00AM-11:00AM: Abstract Number: 2488

Golimumab Retention Rate in Patients with Rheumatoid Arthritis. Predictors of Long-Term Retention

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

9:00AM-11:00AM: Abstract Number: 2297

Golimumab Versus Tocilizumab in Uveitis Related to Refractory Juvenile Idiopathic Arthritis. National Multicenter Study of 33 Patients

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2069

Gout Is More Frequent in Sickle Cell Disease Than the General Population

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 1955

Health Care Provider Advice for Weight Loss Among US Adults with Arthritis, National Health Interview Survey, 2014

Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

9:00AM-11:00AM: Abstract Number: 2267

Health Related Quality of Life in Lupus: Self-Management- a Modifiable Predictor

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2206

Healthy Weight Loss Is Associated with Improved Pain and Function over 8 Years in Overweight Subjects with Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies

9:00AM-11:00AM: Abstract Number: 2381

Hematologic Abnormalities during the Use of Low Dose Methotrexate for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].